Patent details

EP3706739 Title: USE OF RILUZOLE PRODRUGS TO TREAT ATAXIAS

Basic Information

Publication number:
EP3706739
PCT Application Number:
US2018060232
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP188767792
PCT Publication Number:
WO2019094851
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
USE OF RILUZOLE PRODRUGS TO TREAT ATAXIAS
French Title of Invention:
UTILISATION DE PROMÉDICAMENTS À BASE DE RILUZOLE POUR TRAITER DES ATAXIES
German Title of Invention:
VERWENDUNG VON RILUZOLPRODRUGS ZUR BEHANDLUNG VON ATAXIEN
SPC Number:

Dates

Filing date:
11/11/2018
Grant date:
16/10/2024
EP Publication Date:
16/09/2020
PCT Publication Date:
16/05/2019
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
16/10/2024
EP B1 Publication Date:
16/10/2024
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
11/11/2038
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
09/10/2024
 
 

Name:
Biohaven Therapeutics Ltd.
Address:
215 Church Street, New Haven, CT 06510, United States (US)

Agent

Name:
MARKS & CLERK LLP
From:
11/11/2024
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
CORIC, Vladimir
Address:
United States (US)

2

Name:
L'ITALIEN, Gilbert
Address:
United States (US)

3

Name:
BEINER, Melissa
Address:
United States (US)

4

Name:
BERMAN, Robert
Address:
United States (US)

Priority

1

Priority Number:
201762584856 P
Priority Date:
12/11/2017
Priority Country:
United States (US)

2

Priority Number:
201862717948 P
Priority Date:
13/08/2018
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/428; A61K 31/427; A61K 31/4985; A61P 35/00; C07D 277/82; C07D 417/12; A61K 9/48; A61K 9/20; A61P 25/14;

Publication

European Patent Bulletin

Issue number:
202442
Publication date:
16/10/2024
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
01/12/2025
Annual Fee Number:
8
Annual Fee Amount:
99 Euro
Expected Payer:
Last Annual Fee Payment Date:
12/11/2024
Last Annual Fee Paid Number:
7
Last Annual Fee Paid Amount:
82 Euro
Payer:
MARKS & CLERK LLP
Filing date Document type Number of pages
11/11/2024 Power Of Attorney 1
11/11/2024 Outgoing Correspondence 1